Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 391

1.

Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results.

Kovatchev B, Cobelli C, Renard E, Anderson S, Breton M, Patek S, Clarke W, Bruttomesso D, Maran A, Costa S, Avogaro A, Dalla Man C, Facchinetti A, Magni L, De Nicolao G, Place J, Farret A.

J Diabetes Sci Technol. 2010 Nov 1;4(6):1374-81.

2.

Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: preliminary studies in Padova and Montpellier.

Bruttomesso D, Farret A, Costa S, Marescotti MC, Vettore M, Avogaro A, Tiengo A, Dalla Man C, Place J, Facchinetti A, Guerra S, Magni L, De Nicolao G, Cobelli C, Renard E, Maran A.

J Diabetes Sci Technol. 2009 Sep 1;3(5):1014-21.

3.

Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: the Virginia experience.

Clarke WL, Anderson S, Breton M, Patek S, Kashmer L, Kovatchev B.

J Diabetes Sci Technol. 2009 Sep 1;3(5):1031-8.

4.

Overnight closed-loop insulin delivery with model predictive control: assessment of hypoglycemia and hyperglycemia risk using simulation studies.

Wilinska ME, Budiman ES, Taub MB, Elleri D, Allen JM, Acerini CL, Dunger DB, Hovorka R.

J Diabetes Sci Technol. 2009 Sep 1;3(5):1109-20.

5.

Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study.

Thabit H, Lubina-Solomon A, Stadler M, Leelarathna L, Walkinshaw E, Pernet A, Allen JM, Iqbal A, Choudhary P, Kumareswaran K, Nodale M, Nisbet C, Wilinska ME, Barnard KD, Dunger DB, Heller SR, Amiel SA, Evans ML, Hovorka R.

Lancet Diabetes Endocrinol. 2014 Sep;2(9):701-9. doi: 10.1016/S2213-8587(14)70114-7. Epub 2014 Jun 16.

6.

Feasibility study of automated overnight closed-loop glucose control under MD-logic artificial pancreas in patients with type 1 diabetes: the DREAM Project.

Nimri R, Atlas E, Ajzensztejn M, Miller S, Oron T, Phillip M.

Diabetes Technol Ther. 2012 Aug;14(8):728-35. doi: 10.1089/dia.2012.0004.

PMID:
22853723
7.

The university of Virginia/Padova type 1 diabetes simulator matches the glucose traces of a clinical trial.

Visentin R, Dalla Man C, Kovatchev B, Cobelli C.

Diabetes Technol Ther. 2014 Jul;16(7):428-34. doi: 10.1089/dia.2013.0377. Epub 2014 Feb 26.

8.

The "Glucositter" overnight automated closed loop system for type 1 diabetes: a randomized crossover trial.

Nimri R, Danne T, Kordonouri O, Atlas E, Bratina N, Biester T, Avbelj M, Miller S, Muller I, Phillip M, Battelino T.

Pediatr Diabetes. 2013 May;14(3):159-67. doi: 10.1111/pedi.12025. Epub 2013 Feb 28.

PMID:
23448393
9.

2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.

Kropff J, Del Favero S, Place J, Toffanin C, Visentin R, Monaro M, Messori M, Di Palma F, Lanzola G, Farret A, Boscari F, Galasso S, Magni P, Avogaro A, Keith-Hynes P, Kovatchev BP, Bruttomesso D, Cobelli C, DeVries JH, Renard E, Magni L; AP@home consortium.

Lancet Diabetes Endocrinol. 2015 Dec;3(12):939-47. doi: 10.1016/S2213-8587(15)00335-6. Epub 2015 Sep 30.

PMID:
26432775
10.

Multicenter closed-loop insulin delivery study points to challenges for keeping blood glucose in a safe range by a control algorithm in adults and adolescents with type 1 diabetes from various sites.

Zisser H, Renard E, Kovatchev B, Cobelli C, Avogaro A, Nimri R, Magni L, Buckingham BA, Chase HP, Doyle FJ 3rd, Lum J, Calhoun P, Kollman C, Dassau E, Farret A, Place J, Breton M, Anderson SM, Dalla Man C, Del Favero S, Bruttomesso D, Filippi A, Scotton R, Phillip M, Atlas E, Muller I, Miller S, Toffanin C, Raimondo DM, De Nicolao G, Beck RW; Control to Range Study Group.

Diabetes Technol Ther. 2014 Oct;16(10):613-22. doi: 10.1089/dia.2014.0066. Epub 2014 Jul 8. Erratum in: Diabetes Technol Ther. 2015 Jan;17(1):68. Vistenin, Roberto [corrected to Visentin, Roberto].

11.

Control to range for diabetes: functionality and modular architecture.

Kovatchev B, Patek S, Dassau E, Doyle FJ 3rd, Magni L, De Nicolao G, Cobelli C; Juvenile Diabetes Research Foundation Artificial Pancreas Consortium.

J Diabetes Sci Technol. 2009 Sep 1;3(5):1058-65.

12.

Unsupervised home use of an overnight closed-loop system over 3-4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes.

Thabit H, Elleri D, Leelarathna L, Allen JM, Lubina-Solomon A, Stadler M, Walkinshaw E, Iqbal A, Choudhary P, Wilinska ME, Barnard KD, Heller SR, Amiel SA, Evans ML, Dunger DB, Hovorka R.

Diabetes Obes Metab. 2015 May;17(5):452-8. doi: 10.1111/dom.12427. Epub 2015 Jan 9.

13.

An integrated multivariable artificial pancreas control system.

Turksoy K, Quinn LT, Littlejohn E, Cinar A.

J Diabetes Sci Technol. 2014 May;8(3):498-507. doi: 10.1177/1932296814524862. Epub 2014 Apr 7.

14.

Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas.

Kovatchev BP, Renard E, Cobelli C, Zisser HC, Keith-Hynes P, Anderson SM, Brown SA, Chernavvsky DR, Breton MD, Mize LB, Farret A, Place J, Bruttomesso D, Del Favero S, Boscari F, Galasso S, Avogaro A, Magni L, Di Palma F, Toffanin C, Messori M, Dassau E, Doyle FJ 3rd.

Diabetes Care. 2014 Jul;37(7):1789-96. doi: 10.2337/dc13-2076. Epub 2014 Jun 14.

15.

Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.

Haidar A, Legault L, Dallaire M, Alkhateeb A, Coriati A, Messier V, Cheng P, Millette M, Boulet B, Rabasa-Lhoret R.

CMAJ. 2013 Mar 5;185(4):297-305. doi: 10.1503/cmaj.121265. Epub 2013 Jan 28.

16.

Multicenter outpatient dinner/overnight reduction of hypoglycemia and increased time of glucose in target with a wearable artificial pancreas using modular model predictive control in adults with type 1 diabetes.

Del Favero S, Place J, Kropff J, Messori M, Keith-Hynes P, Visentin R, Monaro M, Galasso S, Boscari F, Toffanin C, Di Palma F, Lanzola G, Scarpellini S, Farret A, Kovatchev B, Avogaro A, Bruttomesso D, Magni L, DeVries JH, Cobelli C, Renard E; AP@home Consortium.

Diabetes Obes Metab. 2015 May;17(5):468-76. doi: 10.1111/dom.12440. Epub 2015 Feb 16.

PMID:
25600304
17.

Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies.

Hovorka R, Kumareswaran K, Harris J, Allen JM, Elleri D, Xing D, Kollman C, Nodale M, Murphy HR, Dunger DB, Amiel SA, Heller SR, Wilinska ME, Evans ML.

BMJ. 2011 Apr 13;342:d1855. doi: 10.1136/bmj.d1855.

18.

Artificial pancreas using a personalized rule-based controller achieves overnight normoglycemia in patients with type 1 diabetes.

Capel I, Rigla M, García-Sáez G, Rodríguez-Herrero A, Pons B, Subías D, García-García F, Gallach M, Aguilar M, Pérez-Gandía C, Gómez EJ, Caixàs A, Hernando ME.

Diabetes Technol Ther. 2014 Mar;16(3):172-9. doi: 10.1089/dia.2013.0229. Epub 2013 Oct 23.

19.

A bio-inspired glucose controller based on pancreatic β-cell physiology.

Herrero P, Georgiou P, Oliver N, Johnston DG, Toumazou C.

J Diabetes Sci Technol. 2012 May 1;6(3):606-16.

20.

Efficacy determinants of subcutaneous microdose glucagon during closed-loop control.

Russell SJ, El-Khatib FH, Nathan DM, Damiano ER.

J Diabetes Sci Technol. 2010 Nov 1;4(6):1288-304.

Supplemental Content

Support Center